Zevra Therapeutics, Inc. Selling, General and Administrative Expense
Zevra Therapeutics, Inc. (ZVRA) reported Selling, General and Administrative Expense of $16.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- Zevra Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $16.56M, a 20.32% decline year-over-year.
- Zevra Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $20.78M, a 6.33% increase year-over-year.
- Zevra Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $20.35M, a 26.23% increase year-over-year.
- Zevra Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $16.93M, a 4.49% increase year-over-year.
- Zevra Therapeutics, Inc. selling, general and administrative expense for fiscal 2025 was $77.62M, a 41.46% increase from fiscal 2024.
- Zevra Therapeutics, Inc. selling, general and administrative expense for fiscal 2024 was $54.87M, a 59.90% increase from fiscal 2023.
- Zevra Therapeutics, Inc. selling, general and administrative expense for fiscal 2023 was $34.31M, a 128.18% increase from fiscal 2022.
- Zevra Therapeutics, Inc. selling, general and administrative expense for fiscal 2022 was $15.04M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $16.56M 10-Q · filed 2026-08-05 | $37.34M 10-Q · filed 2026-08-05 | $57.70M derived: sum of 3 quarters · filed 2026-08-05 | $74.63M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $20.78M 10-Q · filed 2026-05-06 | $41.14M derived: sum of 2 quarters · filed 2026-05-06 | $58.07M derived: sum of 3 quarters · filed 2026-05-06 | $78.85M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $20.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $37.29M derived: sum of 2 quarters · filed 2026-03-09 | $58.07M derived: sum of 3 quarters · filed 2026-08-05 | $77.62M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $16.93M 10-Q · filed 2025-11-05 | $37.72M derived: sum of 2 quarters · filed 2026-08-05 | $57.26M 10-Q · filed 2025-11-05 | $73.39M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $20.78M 10-Q · filed 2026-08-05 | $40.33M 10-Q · filed 2026-08-05 | $56.45M derived: sum of 3 quarters · filed 2026-08-05 | $72.66M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $19.55M 10-Q · filed 2026-05-06 | $35.67M derived: sum of 2 quarters · filed 2026-05-06 | $51.88M derived: sum of 3 quarters · filed 2026-05-06 | $64.48M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $16.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $32.33M derived: sum of 2 quarters · filed 2026-03-09 | $44.94M derived: sum of 3 quarters · filed 2026-03-09 | $54.87M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $16.21M 10-Q · filed 2025-11-05 | $28.81M derived: sum of 2 quarters · filed 2025-11-05 | $38.74M 10-Q · filed 2025-11-05 | $53.40M derived: sum of 4 quarters · filed 2025-11-05 | |
| 2024-06-30 | $12.60M 10-Q · filed 2025-08-12 | $22.54M 10-Q · filed 2025-08-12 | $37.19M derived: sum of 3 quarters · filed 2025-08-12 | $43.01M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $9.93M 10-Q · filed 2025-05-13 | $24.59M derived: sum of 2 quarters · filed 2025-05-13 | $30.41M derived: sum of 3 quarters · filed 2025-05-13 | $37.02M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $14.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $20.48M derived: sum of 2 quarters · filed 2025-03-12 | $27.09M derived: sum of 3 quarters · filed 2025-03-12 | $34.31M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $5.82M 10-Q · filed 2024-11-13 | $12.43M derived: sum of 2 quarters · filed 2024-11-13 | $19.66M 10-Q · filed 2024-11-13 | $24.43M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $6.61M 10-Q · filed 2024-08-14 | $7.00M 10-Q · filed 2023-08-14 | $13.84M 10-Q · filed 2024-08-14 | $18.61M derived: sum of 3 quarters · filed 2024-08-14 | $22.59M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $7.23M 10-Q · filed 2024-05-09 | $6.83M 10-Q · filed 2023-05-15 | $12.00M derived: sum of 2 quarters · filed 2024-05-09 | $15.97M derived: sum of 3 quarters · filed 2024-05-09 | $19.53M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $4.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $8.75M derived: sum of 2 quarters · filed 2024-04-01 | $12.30M derived: sum of 3 quarters · filed 2024-04-01 | $15.04M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $3.97M 10-Q · filed 2023-11-07 | $7.53M derived: sum of 2 quarters · filed 2023-11-07 | $10.27M 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $3.56M 10-Q · filed 2023-08-14 | $6.29M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $2.73M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |